Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Cel-Sci Corp (AMEX:CVM) (was HIV)

No earlier versions found for this Subject.

Return to Cel-Sci Corp (AMEX:CVM) (was HIV)

July 12, 1996

Cel-Sci corp announced that 78% of the SCID mice injected with blood of humans vaccinated with Cel-Sci's HGP-30 vaccine were protected against HIV challenge. This has proved to be a significant step in the progress of HGP-30's quest toward becoming the latest weapon in fighting HIV. Cel-Sci is a great company with an excellent research program showing excellent potential. I like it's prospects down the road as it also pursues methods of treating cancer. I think in light of the recent general sell-off in the market it is a good time to buy.

Giuseppe Scalamogna